代谢组学衍生评分可预测代谢功能障碍相关脂肪性肝炎及肝病死亡
该研究基于311例中国成人肝活检队列,利用44项临床参数和250种血清代谢物通过机器学习构建MASH预测评分,并在芬兰肝活检队列(n=305)外部验证。评分在中国和芬兰队列识别MASH的AUROC分别为0.87和0.81;在中国上海长风研究(n=5,893)和英国生物银行(n=111,673)中,中/高风险者MASLD相关死亡风险显著高于低风险者。
要点
- MASH预测评分包含BMI、天冬氨酸氨基转移酶、酪氨酸和VLDL磷脂与总脂质比值。
- 评分在中国和芬兰肝活检队列识别MASH的AUROC分别为0.87和0.81,阴性预测值高。
- 评分预测MASLD相关死亡优于FIB-4和NAFLD纤维化评分。
核心结论
- 代谢组学衍生的MASH预测评分能准确预测中国和欧洲人群的MASH风险及MASLD相关死亡。
研究设计与样本
- 基于311例中国成人肝活检队列,用44项临床参数和250种血清代谢物通过多步机器学习策略构建MASH预测评分。
- 在芬兰肝活检队列(n=305)中进行外部验证。
- 在基于人群的上海长风研究(n=5,893)和英国生物银行(n=111,673)中分析评分与全因及病因特异性死亡的关联。
主要发现
- 中国肝活检队列中,24项临床参数和194种血清代谢物与MASH显著相关。
- 最终MASH评分包括BMI、天冬氨酸氨基转移酶、酪氨酸和VLDL中磷脂与总脂质比值。
- 评分在中国和芬兰队列识别MASH的AUROC分别为0.87(95% CI 0.83-0.91)和0.81(95% CI 0.75-0.88),阴性预测值高。
- 中/高风险者较低风险者MASLD相关死亡风险:中国人群HR 23.19(95% CI 4.80-111.97),随访7.2年;欧洲人群HR 20.15(95% CI 10.95-37.11),随访12.6年。
- 评分预测MASLD相关死亡优于FIB-4和NAFLD纤维化评分。
临床怎么用
- 作者认为,该MASH预测评分是识别高危和一般人群中严重肝脏相关结局风险显著升高个体的有用工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) is associated with a >10-fold increase in liver-related mortality. However, biomarkers predicting both MASH and mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are missing. We developed a metabolome-derived prediction score for MASH and examined whether it predicts mortality in Chinese and European cohorts. METHODS: The MASH prediction score was developed using a multi-step machine learning strategy, based on 44 clinical parameters and 250 serum metabolites measured by proton nuclear magnetic resonance in 311 Chinese adults undergoing a liver biopsy. External validation was conducted in a Finnish liver biopsy cohort (n = 305). We investigated associations of the score with all-cause and cause-specific mortality in the population-based Shanghai Changfeng study (n = 5,893) and the UK biobank (n = 111,673). RESULTS: A total of 24 clinical parameters and 194 serum metabolites were significantly associated with MASH in the Chinese liver biopsy cohort. The final MASH score included BMI, aspartate aminotransferase, tyrosine, and the phospholipid-to-total lipid ratio in VLDL. The score identified patients with MASH with AUROCs of 0.87 (95% CI 0.83-0.91) and 0.81 (95% CI 0.75-0.88) in the Chinese and Finnish cohorts, with high negative predictive values. Participants with a high or intermediate risk of MASH based on the score had a markedly higher risk of MASLD-related mortality than those with a low risk in Chinese (hazard ratio 23.19; 95% CI 4.80-111.97) and European (hazard ratio 20.15; 95% CI 10.95-37.11) individuals after 7.2 and 12.6 years of follow-up, respectively. The MASH prediction score was superior to the Fibrosis-4 index and the NAFLD fibrosis score in predicting MASLD-related mortality. CONCLUSION: The metabolome-derived MASH prediction score accurately predicts risk of MASH and MASLD-related mortality in both Chinese and European individuals. IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatohepatitis (MASH) is associated with more than a 10-fold increase in liver-related death. However, biomarkers predicting not only MASH, but also death due to liver disease, are missing. We established a MASH prediction score based on 44 clinical parameters and 250 serum metabolites using a machine learning strategy. This metabolome-derived MASH prediction score could accurately identify patients with MASH among both Chinese and Finnish individuals, and it was superior to the Fibrosis-4 index and the NAFLD fibrosis score in predicting MASLD-related death in the general population. Thus, the new MASH prediction score is a useful tool for identifying individuals with a markedly increased risk of serious liver-related outcomes among at-risk and general populations.
引用
- Huang Q, Qadri SF, Bian H, et al. A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease. J Hepatol. 2024. PMID: 39423864. doi:10.1016/j.jhep.2024.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。